Karl-Henning Kalland

Dr. Karl-Henning Kalland

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2009 in PLOS ONE
Verified
Journal Article
Open access
PDF file
XKXi-Song Ke
Xi-Song Ke
YQYi Qu
Yi Qu
KRKari Rostad
Kari Rostad
WLWen-Cheng Li
Wen-Cheng Li
BLBiaoyang Lin
Biaoyang Lin
KKKarl-Henning Kalland
Karl-Henning Kalland
Increasing evidence implicates the critical roles of epigenetic regulation in cancer. Very recent reports indicate that global gene silencing in cancer is associated with specific epigenetic modifications. However, the relationship between epigenetic switches and more dynamic patterns of gene activation and repression has remained largely unknown. Genome-wide profiling of the trimethylation of histone H3 lysine 4 (H3K4me3) and lysine 27 (H3K27me3) was performed using chromatin immunoprecipitation coupled with whole genome promoter microarray (ChIP-chip) techniques. Comparison of the ChIP-chip data and microarray gene expression data revealed that loss and/or gain of H3K4me3 and/or H3K27me3 were strongly associated with differential gene expression, including microRNA expression, between prostate cancer and primary cells. The most common switches were gain or loss of H3K27me3 coupled with low effect on gene expression. The least prevalent switches were between H3K4me3 and H3K27me3 coupled with much higher fractions of activated and silenced genes. Promoter patterns of H3K4me3 and H3K27me3 corresponded strongly with coordinated expression changes of regulatory gene modules, such as HOX and microRNA genes, and structural gene modules, such as desmosome and gap junction genes. A number of epigenetically switched oncogenes and tumor suppressor genes were found overexpressed and underexpressed accordingly in prostate cancer cells. This work offers a dynamic picture of epigenetic switches in carcinogenesis and contributes to an overall understanding of coordinated regulation of gene expression in cancer. Our data indicate an H3K4me3/H3K27me3 epigenetic signature of prostate carcinogenesis.

16 August 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
YQYi Qu
Yi Qu
NGNaouel Gharbi
Naouel Gharbi
XYXing Yuan
Xing Yuan
JOJan Roger Olsen
Jan Roger Olsen
PBPernille Blicher
Pernille Blicher
XKXisong Ke
Xisong Ke
Oncogenic mutations of the Wnt (wingless)/β-catenin pathway are frequently observed in major cancer types. Thus far, however, no therapeutic agent targeting Wnt/β-catenin signaling is available for clinical use. Here we demonstrate that axitinib, a clinically approved drug, strikingly blocks Wnt/β-catenin signaling in cancer cells, zebrafish, and Apcmin/+ mice. Notably, axitinib dramatically induces Wnt asymmetry and nonrandom DNA segregation in cancer cells by promoting nuclear β-catenin degradation independent of the GSK3β (glycogen synthase kinase3β)/APC (adenomatous polyposis coli) complex. Using a DARTS (drug affinity-responsive target stability) assay coupled to 2D-DIGE (2D difference in gel electrophoresis) and mass spectrometry, we have identified the E3 ubiquitin ligase SHPRH (SNF2, histone-linker, PHD and RING finger domain-containing helicase) as the direct target of axitinib in blocking Wnt/β-catenin signaling. Treatment with axitinib stabilizes SHPRH and thereby increases the ubiquitination and degradation of β-catenin. Our findings suggest a previously unreported mechanism of nuclear β-catenin regulation and indicate that axitinib, a clinically approved drug, would provide therapeutic benefits for cancer patients with aberrant nuclear β-catenin activation. Significance The Wnt (wingless)/β-catenin signaling pathway is an attractive target for cancer therapy. However, known Wnt inhibitors are still far from clinical use. Here we report that the clinically approved drug axitinib strongly inhibits Wnt/β-catenin signaling in vitro and in vivo. In particular, a phenotype of Wnt inhibition called “Wnt asymmetry” was revealed in axitinib-treated cancer cells. The identification of E3 ubiquitin ligase SHPRH (SNF2, histone-linker, PHD and RING finger domain-containing helicase) as the functional target implies that axitinib blocking of Wnt signaling is independent of genetic mutations that are frequently observed in cancer patients. Collectively, our results suggest a mechanism of nuclear β-catenin regulation and highlight axitinib as a promising therapeutic agent for cancer patients with aberrant Wnt/β-catenin signaling.

25 January 2013 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
YQYi Qu
Yi Qu
WLWen‐Cheng Li
Wen‐Cheng Li
MHMargrete Reime Hellem
Margrete Reime Hellem
KRKari Rostad
Kari Rostad
MPMihaela Popa
Mihaela Popa
XKXi‐Song Ke
Xi‐Song Ke
MicroRNAs play critical roles in tumorigenesis and metastasis. Here, we report the dual functions of miR‐182 and miR‐203 in our previously described prostate cell model. MiR‐182 and miR‐203 were completely repressed during epithelial to mesenchymal transition (EMT) from prostate epithelial EP156T cells to the progeny mesenchymal nontransformed EPT1 cells. Re‐expression of miR‐182 or miR‐203 in EPT1 cells and prostate cancer PC3 cells induced mesenchymal to epithelial transition (MET) features. Simultaneously, miR‐182 and miR‐203 provided EPT1 cells with the ability to self‐sufficiency of growth signals, a well‐recognized oncogenic feature. Gene expression profiling showed high overlap of the genes affected by miR‐182 and miR‐203. SNAI2 was identified as a common target of miR‐182 and miR‐203. Knock‐down of SNAI2 in EPT1 cells phenocopied re‐expression of either miR‐182 or miR‐203 regarding both MET and self‐sufficiency of growth signals. Strikingly, considerable overlaps of changed genes were found between the re‐expression of miR‐182/203 and knock‐down of SNAI2. Finally, P‐cadherin was identified as a direct target of SNAI2. We conclude that miR‐182 and miR‐203 induce MET features and growth factor independent growth via repressing SNAI2 in prostate cells. Our findings shed new light on the roles of miR‐182/203 in cancer related processes.

25 November 2010 in BMC Genomics
Verified
Journal Article
Open access
PDF file
XKXi-Song Ke
Xi-Song Ke
YQYi Qu
Yi Qu
YCYang Cheng
Yang Cheng
WLWen-Cheng Li
Wen-Cheng Li
VRVarda Rotter
Varda Rotter
KKKarl-Henning Kalland
Karl-Henning Kalland
Previously we reported extensive gene expression reprogramming during epithelial to mesenchymal transition (EMT) of primary prostate cells. Here we investigated the hypothesis that specific histone and DNA methylations are involved in coordination of gene expression during EMT.

13 October 2008 in PLOS ONE
Verified
Journal Article
Open access
PDF file
XKXi-Song Ke
Xi-Song Ke
YQYi Qu
Yi Qu
NGNaomi Goldfinger
Naomi Goldfinger
KRKari Rostad
Kari Rostad
RHRandi Hovland
Randi Hovland
KKKarl-Henning Kalland
Karl-Henning Kalland
Epithelial to mesenchymal transition (EMT) has been connected with cancer progression in vivo and the generation of more aggressive cancer cell lines in vitro. EMT has been induced in prostate cancer cell lines, but has previously not been shown in primary prostate cells. The role of EMT in malignant transformation has not been clarified. In a transformation experiment when selecting for cells with loss of contact inhibition, the immortalized prostate primary epithelial cell line, EP156T, was observed to undergo EMT accompanied by loss of contact inhibition after about 12 weeks in continuous culture. The changed new cells were named EPT1. EMT of EPT1 was characterized by striking morphological changes and increased invasion and migration compared with the original EP156T cells. Gene expression profiling showed extensively decreased epithelial markers and increased mesenchymal markers in EPT1 cells, as well as pronounced switches of gene expression modules involved in cell adhesion and attachment. Transformation assays showed that EPT1 cells were sensitive to serum or growth factor withdrawal. Most importantly, EPT1 cells were not able to grow in an anchorage-independent way in soft agar, which is considered a critical feature of malignant transformation. This work for the first time established an EMT model from primary prostate cells. The results show that EMT can be activated as a coordinated gene expression program in association with early steps of transformation. The model allows a clearer identification of the molecular mechanisms of EMT and its potential role in malignant transformation.

23 July 2009 in APMIS
Verified
Journal Article
Closed access
PDF file
KRKari Rostad
Kari Rostad
OHOlaf J. C. Hellwinkel
Olaf J. C. Hellwinkel
SHSvein A. Haukaas
Svein A. Haukaas
OHOle J. Halvorsen
Ole J. Halvorsen
AØAnne M. Øyan
Anne M. Øyan
KKKarl-Henning Kalland
Karl-Henning Kalland